---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-025148"
form_type: "8-K"
ticker: "AUPH"
cik: "0001600620"
company_name: "Aurinia Pharmaceuticals Inc."
filed_at: "2022-09-19T23:59:59+00:00"
generated_at: "2026-06-23T08:49:38.313274+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Aurinia receives EU marketing authorization for LUPKYNIS; director Walbert resigns

## Summary
- EC grants marketing authorization for LUPKYNIS (voclosporin) to treat active lupus nephritis in EU, Iceland, Liechtenstein, Norway, and Northern Ireland.
- Aurinia to receive $30M milestone payment from Otsuka for EC approval; cash within 30 days of invoicing.
- Director Timothy P. Walbert resigns from Board effective Sept. 19, 2022; no disagreement with company.
- LUPKYNIS previously received FDA approval in Jan. 2021 for same indication.

## SEC filing metadata
- accession: 0001628280-22-025148
- form_type: 8-K
- ticker: AUPH
- cik: 0001600620
- company_name: Aurinia Pharmaceuticals Inc.
- filed_at: 2022-09-19T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1600620/000162828022025148/0001628280-22-025148-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1600620/000162828022025148/auph-20220919.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-025148
- JSON: https://secwatch.observer/filing/0001628280-22-025148.json
- Plain text: https://secwatch.observer/filing/0001628280-22-025148.txt

## Key facts
- Executive change
  Timothy P. Walbert resigned as Director at Aurinia Pharmaceuticals Inc..
  - Action: resigned
  - Role: Director
  source text: On September 19, 2022, Timothy P. Walbert, a member of the board of directors (the Board) of Aurinia, notified the Company of his intent to resign from the Board, effective at the close of business on September 19, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1600620/000162828022025148/0001628280-22-025148-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.